Addition of Etoposide to Initial Therapy of Adult Acute Lymphoblastic Leukemia: A Combined Clinicaland Laboratory Study

Leukemia and Lymphoma

Volumn 23, Issue 42006, 1996, Pages 71-83

  Kaufmann, Scott H ^a,b   Karp, Judith E ^a   Burke, Philip J ^a   Gore, Steven D ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

daunorubicin; Drug resistance; etoposide; P glycoprotein; topoisomerase II

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME ANTIBODY; ETOPOSIDE; GLYCOPROTEIN P; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPEROXIDASE STAINING; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MALE; MICROFLUOROMETRY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TUMOR CELLS, CULTURED;

EID: 0029801162     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199609054804     Document Type: Article

References (72)

1. O'Reilly S. E., Klimo P., Connors J. M. The Evolving Role of Etoposide in the Management of Lymphomas and Hodgkin's Disease. Cancer 1991; 67: 271 – 280
2. Sonneveld P. Teniposide in Lymphomas and Leukemias. Seminars in Oncology 1992; 19: 59 – 64
3. Young R. C. Etoposide in the Treatment of Non-Hodgkin's Lymphomas. Seminars in Oncology 1992; 19: 19 – 25
4. Urba W. J., Wilson W. H., Duffey P. L., Wittes R., Chabner B. A., Longo D. L. Recent National Cancer Institute Lymphoma Trials of Etoposide-Containing Combination Chemotherapy. Seminars in Oncology 1992; 19: 26 – 32
5. Hainsworth J. D. Chronic Administration of Etoposide in the Treatment of Non-Hodgkin's Lymphoma. Leukemia and Lymphoma 1993; 10: 65 – 72
6. Herzig R. H. High-Dose Etoposide and Marrow Transplantation. Cancer 1991; 67: 292 – 298
7. Blume K. G., Forman S. J. High-Dose Etoposide (VP-16)-Containing Preparatory Regimens in Allogeneic and Autologous Bone Marrow Transplantation for Hematologic Malignancies. Seminars in Oncology 1992; 19: 63 – 66
8. Snyder D. S., Chao N. J., Amylon M. D., Taguchi J., Long G. D., Negrin R. S., Nademanee A. P., O'Donnell M. R., Schmidt G. M., Stein A. S., Parker P. M., Smith E. P., Stepan D. E., Molina A., Lipsett J. A., Hoppe R. T., Niland J. C., Dagis A. C., Wong R. M., Forman S. J., Blume K. G. Fractionated Total Body Irradiation and High-Dose Etoposide as a Preparatory Regimen for Bone Marrow Transplantation for 99 Patients with Acute Leukemia in First Complete Remission. Blood 1993; 82: 2920 – 2928
9. Rivera G. K., Raimondi S. C., Hancock M. L., Behm F. G., Pui C. H., Abromowitch M., Mirro J., Jr., Ochs J. S., Look A. T., Williams D. L., Murphy S. B., Dahl G. V., Kalwinsky D. K., Evans W. E., Kun L. E., Simone J. V., Christ W. M. Improved Outcome in Childhood Acute Lymphoblastic Leukaemia with Reinforced Early Treatment and Rotational Combination Chemotherapy. Lancet 1991; 337: 61 – 66
10. Rivera G. K., Evans W. E. Clinical Trials of Teniposide (VM-26) in Childhood Acute Lymphocytic Leukemia. Seminars in Oncology 1992; 19: 51 – 58
11. Copelan E. A., McGuire E. A. The Biology and Treatment of Acute Lymphoblastic Leukemia in Adults. Blood 1995; 85: 1151 – 1168
12. Bishop J. F. Etoposide in the Treatment of Leukemias. Seminars in Oncology 1992; 19: 33 – 38
13. Ross W. E., Sullivan D. M., Chow K.-C. Advances in Oncology 1988, V. E. Devita, S. Hellman, S. A. Rosenberg. J. B. Lippincott Co., Philadelphia, PA 1988; 65 – 81
14. Chen A. Y., Liu L. F. DNA Topoisomerases: Essential Enzymes and Lethal Targets. Annual Review of Pharmacology and Toxicology 1994; 34: 191 – 218
15. Pommier Y., Leteurtre F., Fesen M. R., Fujimori A., Bertrand R., Solary E., Kohlhagen G., Kohn K. W. Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors. Cancer Investigation 1994; 12: 530 – 542
16. Tewey K. M., Rowe T. C., Yang L., Halligan B. D., Liu L. F. Adriamycin-Induced DNA Damage by Mammalian DNA Topoisomerases II. Science 1984; 226: 466 – 468
17. Wassermann K., Markovits J., Jaxel C., Capranico G., Kohn K. W., Pommier Y. Effects of Morpholinyl Doxorubicins, Doxorubicin, and Actinomycin D on Mammalian DNA Topoisomerases I and II. Molecular Pharmacology 1990; 38: 38 – 45
18. Deffie A. M., McPherson J. P., Gupta R. S., Hedley D. W., Goldenberg G. J. Multifactorial Resistance to Antineoplastic Agents in Drug-Resistant P388 Murine Leukemia, Chinese Hamster Ovary, and Human HeLa Cells, with Emphasis on the Role of DNA Topoisomerase II. Biochemistry and Cell Biology 1992; 70: 354 – 364
19. Beck W. T., Danks M. K., Wolverton J. S., Kim R., Chen M. Drug Resistance Associated with Altered DNA Topoisomerase II. Advances in Enzyme Regulation 1993; 33: 113 – 127
20. Peereboom D., Charron M., Kaufmann S. H. Topoisomerase in Human Leukemia. Advances in Pharmacology 1994; 29B: 33 – 50
21. Froelich-Ammon S. J., Osheroff N. Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism. Journal of Biological Chemistry 1995; 270: 21429 – 21432
22. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S.-L., Gazdar A., Pirker R., Green A., Crist W., Brodear G. M., Lieber M., Cossman J., Gottesman M. M., Pastan I. Expression of a Multidrug Resistance Gene in Human Cancers. Journal of the National Cancer Institute 1989; 81: 116 – 124
23. Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of mdr1 and mdr3 Multidrug-Resistance Genes in Human Acute and Chronic Leukemias and Association with Stimulation of Drug Accumulation by Cyclosporine. Journal of the National Cancer Institute 1990; 82: 1133 – 1140
24. Marie J.-P., Zittoun R., Sikic B. I. Multidrug Resistance (mdr1) Gene Expression in Adult Acute Leukemias: Correlations with Treatment Outcome and In Vitro Drug Sensitivity. Blood 1991; 78: 586 – 592
25. Gekeler V., Frese G., Noller A., Handgretinger R., Wilisch A., Schmidt H., Muller C. P., Dopfer R., Klingebiel T., Diddens H., Probst H., Niethammer D. Mdr1/P-Glycoprotein, Topoisomerase, and Glutathione-S-Transferase Pi gene Expression in Primary and Relapsed State Adult and Childhood Leukaemia. British Journal of Cancer 1992; 66: 507 – 517
26. Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., Akiyama S. Expression of the Multidrug Transporter, P-Glycoprotein, in Acute Leukemia Cells and Correlation to Clinical Drug Resistance. Cancer 1990; 66: 868 – 873
27. Kuwazuru Y., Hanada S., Furukawa T., Sumizawa T., Utsunomiya A., Ishibashi K., Saito T., Uozumi K., Maruyama M. Expression of P-Glycoprotein in Adult T-Cell Leukemia Cells. Blood 1990; 76: 2065 – 2071
28. Sugawara I., Kodo H., Ohkochi E., Hamada H., Tsuruo T., Mori S. High-Level Expression of MRK 16 and MRK 20 Murine Monocloncal Antibody-Defined Proteins (170–180,000 P-Glycoprotein and 85,000 Protein) in Leukaemias and Malignant Lymphomas. British Journal of Cancer 1989; 60: 538 – 541
29. Musto P., Cascavilla N., Di Renzo N., Ladogana S., La Sala A., Melillo L., Nobile M., Matera R., Lombardi G., Carotenuto M. Clinical Relevance of Immunocytochemical Detection of Multidrug-Resistance-Associated P-Glycoprotein in Hematologic Malignancies. Tumori 1990; 76: 353 – 359
30. Solary E., Bidan J.-M., Calvo F., Caillot D., Mugneret F., Gauville C., Tsuruo T., Carli P. M., Guy H. P-Glycoprotein Expression and In Vitro Reversion of Doxorubicin Resistance by Verapamil in Clinical Specimens from Acute Leukaemia and Myeloma. Leukemia 1991; 5: 592 – 597
31. Goasguen J. E., Dossot J.-M., Fardel O., Le Mee F., Le Gall E., Leblay R., Leprise P. Y., Chaperon J., Fauchet R. Expression of the Multidrug Resistance-Associated P-Glycoprotein (P-170) in 59 Cases of De Novo Acute Lymphoblastic Leukemia: Prognostic Implications. Blood 1993; 81: 2394 – 2395
32. Rothenberg M. L., Mickley L. A., Cole D. E., Balis F. M., Tsuruo T., Poplack D. G., Fojo A. T. Expression of the MDR 1/P-170 Gene in Patients with Acute Lymphoblastic Leukemia. Blood 1989; 74: 1388 – 1395
33. Ubezio P., Limonta M., D'Incalci M., Damia G., Masera G., Giudici G., Wolverton J. S., Beck W. T. Failure to Detect the P-Glycoprotein Multidrug Resistance Phenotype in Cases of Resistant Childhood Acute Lymphocytic Leukemia. European Journal of Cancer and Clinical Oncology 1989; 25: 1895 – 1899
34. Schneider E., Cowan K. H., Bader H., Toomey S., Schwartz G. N., Karp J. E., Burke P. J., Kaufmann S. H. Increased Expression of the Multidrug Resistance-Associated Protein Gene in Relapsed Acute Leukemia. Blood 1995; 85: 186 – 193
35. Pieters R., Hongo T., Loonen A. H., Huismans D. R., Broxterman H. J., Hählen K., Veerman A. J. P. Different Types of Non-P-Glycoprotein Mediated Multiple Drug Resistance in Children with Relapsed Acute Lymphoblastic Leukaemia. British Journal of Cancer 1992; 65: 691 – 697
36. Gruber A., Vitols S., Norgren S., Areström I., Peterson C., Björkholm M., Reizenstein P., Luthman H. Quantitative Determination of mdr1 Gene Expression in Leukaemic Cells from Patients with Acute Leukaemia. British Journal of Cancer 1992; 66: 266 – 272
37. Ludescher C., Hilbe W., Eisterer W., Thaler J., Gotwald M., Hofmann J. Low Incidence of Activity of P-Glycoprotein (P-170) in De Novo Acute Lymphoblastic Leukemia Determined by a Flow Cytometry Assay. Blood 1993; 82: 3505 – 3507
38. Drake F. H., Hofmann G. A., Bartus H. F., Mattern M. R., Crooke S. T., Mirabelli C. K. Biochemical and Pharmacological Properties of p170 and p180 Forms of Topoisomerase II. Biochemistry 1989; 28: 8154 – 8160
39. Prosperi E., Negri C., Marchese G., Astaldi Ricotti G. C. B. Expression of the 170-kDA and 180 kDA isoform of DNA Topoisomerase II in Resting and Proliferating Human Lymphocytes. Cell Proliferation 1994; 27: 257 – 267
40. Potmesil M., Hsiang Y.-H., Liu L. F., Bank B., Grossberg H., Kirschenbaum S., Forlenza T. J., Penziner A., Kanganis D., Forlenza T. J., Knowles D., Traganos F., Silber R. Resistance of Human Leukemic and Normal Lymphocytes to Drug-Induced DNA Cleavage and Low Levels of DNA Topoisomerase II. Cancer Research 1988; 48: 3537 – 3543
41. Kaufmann S. H., McLaughlin S. J., Kastan M., Liu L. F., Karp J. E., Burke P. J. Topoisomerase II Levels During Granulocytic Maturation in Vitro and in Vivo. Cancer Research 1991; 51: 3534 – 3543
42. Brown G. A., McPherson J. P., Gu L., Hedley D. W., Toso R., Deuchars K. L., Freedman M. H., Goldenberg G. J. Relationship of DNA Topoisomerase II Alpha and Beta Expression to Cytotoxicity of Antineoplastic Agents in Human Acute Lymphoblastic Leukemia Cell Lines. Cancer Research 1995; 55: 78 – 82
43. Edwards C. M., Glisson B. S., King C. K., Smallwood-Kentro S., Ross W. E. Etoposide-Induced DNA Cleavage in Human Leukemia Cells. Cancer Chemotherapy and Pharmacology 1987; 20: 162 – 168
44. Donehower R. C., Karp J. E., Burke P. J. Pharmacology and Toxicity of High-Dose Cytarabine by 72-Hour Continuous Infusion. Cancer Treatment Reports 1986; 70: 1059 – 1065
45. Wingard J. R., Piantadosi S., Santos G. W., Saral R., Vriesendorp H. M., Yeager A. M., Burns W. H., Ambinder R. F., Braine H. G., Elfenbein G., Jones R. J., Kaizer H., May W. S., Rowley S. D., Sensenbrenner L. L., Stuart R. K., Tutschka P. J., Vogelsang G. B., Wagner J. E., Beschorner W. E., Brookmeyer R., Farmer E. R. Allogeneic Bone Marrow Transplantation for Patients with High-Risk Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 1990; 8: 820 – 830
46. Rowley S. D., Miller C. B., Piantadosi S., Davis J. M., Santos G. W., Jones R. J. Phase I Study of Combination Drug Purging for Autologous Bone Marrow Transplantation. Journal of Clinical Oncology 1991; 9: 2210 – 2218
47. Zehnbauer B. A., Pardoll D. M., Burke P. J., Graham M. L., Vogelstein B. Immunoglobulin Gene Rearrangements in Remission Bone Marrow Specimens from Patients with Acute Lymphoblastic Leukemia. Blood 1986; 67: 835 – 838
48. Kaufmann S. H., Karp J. E., Jones R. J., Miller C. B., Schneider E., Zwelling L. A., Cowan K., Wendel K., Burke P. J. Topoisomerase II Levels and Drug Sensitivity in Adult Acute Myelogenous Leukemia. Blood 1994; 83: 517 – 530
49. Minowada J., Ohnuma T., Moore G. E. Rosette-Forming Human Lymphoid Cell Lines. I. Establishment and Evidence for Origin of Thymus-Derived Lymphocytes. Journal of the National Cancer Institute 1972; 49: 891 – 895
50. Willingham M. C., Cornwell M. M., Cardarelli C. O., Gottesman M. M., Pastan I. Single Cell Analysis of Daunomycin Uptake and Efflux in Multi-Drug-Resistant and -Sensitive KB Cells: Effects of Verapamil and Other Drugs. Cancer Research 1986; 46: 5941 – 5946
51. Cole S. P., Downes H. F., Slovak M. L. Effect of Calcium Antagonists on the Chemosensitivity of Two Multidrug-Resistant Human Tumour Cell Lines Which Do Not Overexpress P-Glycoprotein. British Journal of Cancer 1989; 59: 42 – 46
52. Leier I., Jedlitschky G., Buchholz U., Cole S. P., Deeley R. G., Keppler D. The MRP Gene Encodes an ATP-De-pendent Export Pump for Leukotriene C4 and Structurally Related Conjugates. Journal of Biological Chemistry 1994; 269: 27807 – 27810
53. Beck W. T. The Cell Biology of Multiple Drug Resistance. Biochemical Pharmacology 1987; 36: 2879 – 2887
54. Van Der Bliek A. M., Van Der Velde-Koerts T., Ling V., Borst P. Overexpression and Amplification of Five Genes in a Mul-tidrug-Resistant Chinese Hamster Ovary Cell Line. Molecular and Cellular Biology 1986; 6: 1671 – 1678
55. Hendricks C. B., Rowinsky E. K., Grochow L. B., Donehower R. C., Kaufmann S. H. Effect of P-Glycoprotein Expression on the Accumulation and Cytotoxicity of Topotecan (SK&F 104864), a New Camptothecin Analogue. Cancer Research 1992; 52: 2268 – 2278
56. Bjorkholm M. Etoposide and Teniposide in the Treatment of Acute Leukemia. Medical Oncology and Tumor Pharmacotherapy 1990; 7: 3 – 10
57. Abromowitch M., Bowman W. P., Ochs J., Rivera G. Etoposide (VP-16) with Prednisone and Vincristine for the Treatment of Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 1985; 3: 789 – 792
58. Esumi N., Todo S., Arakawa S., Imashuku S. Etoposide and Cytosine Arabinoside Combination Chemotherapy for Refractory Acute Lymphocytic Leukemia in Childhood. Journal of Clinical Oncology 1986; 4: 1089 – 1093
59. Ho A. D., Brado B., Haas R., Hunstein W. Etoposide in Acute Leukemia. Past Experience and Future Perspectives. Cancer 1991; 67: 281 – 284
60. Van Kalken C. K., Broxterman H. J., Pinedo H. M., Feller N., Dekker H., Lankelma J., Giaccone G. Cortisol is Transported by the Multidrug Resistance Gene Product P-Glycoprotein. British Journal of Cancer 1993; 67: 284 – 289
61. Bourgeois S., Gruol D. J., Newby R. F., Rajah F. M. Expression of an MDR Gene is Associated with a New Form of Resistance to Dexamethasone-Induced Apoptosis. Molecular Endocrinology 1993; 7: 840 – 851
62. Holden J. A., Snow G. W., Perkins S. L., Jolles C. J., Kjeldsberg C. R. Immunohistochemical Staining for DNA Topoisomerase II in Frozen and Formalin-Fixed Paraffin-Embedded Human Tissues. Modern Pathology 1994; 7: 829 – 834
63. Sikic B. I. Modulation of Multidrug Resistance: At the Threshold. Journal of Clinical Oncology 1993; 11: 1629 – 1635
64. Gabutti V., Pileri A., Tarocco R. P., Gavosto F., Cooper E. H. Proliferative Potential of Out-of-Cycle Leukemia Cells. Nature 1969; 224: 375 – 376
65. Clarkson B., Fried J., Strife A., Sakai Y., Ota K., Okita T. Studies of Cellular Proliferation in Human Leukemia. Cancer 1970; 25: 1237 – 1260
66. Sparano J. A., Wiernik P. H., Leaf A., Dutcher J. P. Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Relapsed and Resistant Non-Hodgkin's Lymphoma: Evidence for a Schedule-Dependent Effect Favoring Infusional Administation of Chemotherapy. Journal of Clinical Oncology 1993; 11: 1071 – 1079
67. Wilson W. H., Bryant G., Bates S., Fojo A., Wittes R. E., Steinberg S. M., Kohler D. R., Jaffee E. S., Herdt J., Cheson B. D., et al. EPOCH Chemotherapy: Toxicity and Efficacy in Relapsed and Refractory Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 1993; 11: 1573 – 1582
68. Hainsworth J. D., Johnson D. H., Frazier S. R., Greco F. A. Chronic Daily Administration of Oral Etoposide in Refractory Lymphoma. European Journal of Cancer 1990; 26: 818 – 821
69. Thompson D. S., Hainsworth J. D., Hande K. R., Holzmer M. C., Greco F. A. Prolonged Administration of Low-Dose, Incisional Etoposide in Patients with Etoposide-Sensitive Neoplasms: A Phase I/II Study. Journal of Clinical Oncology 1993; 11: 1322 – 1328
70. Andreeff M., Tafuri A., Hegewisch-Becker S. Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) Recruit Myeloblasts and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside. Hamatologie Und Bluttransfusion 1990; 33: 747 – 762
71. Rowinsky E. K., Adjei A. A., Donehower R. C., Gore S. D., Jones R. J., Burke P. J., Cheng Y.-C., Grochow L. B., Kaufmann S. H. A Phase I and Pharmacodynamic Study of the Topoisomerase I-Inhibitor Topotecan in Patients with Refractory Acute Leukemia. Journal of Clinical Oncology 1994; 12: 2193 – 2203
72. Uckun F. M., Stewart C. F., Reaman G., Chelstrom L. M., Jin J., Chandan-Langlie M., Waddick K. G., White J., Evans W. E. In Vitro and In Vivo Activity of Topotecan Against Human B-Lineage Acute Lymphoblastic Leukemia Cells. Blood 1995; 85: 2817 – 2828